The second level includes variants conferring strong or intermediate predisposition to PD with incomplete penetrance (GP+), including SNCA duplications and pathogenic variants in LRRK2, VPS35, CHCHD2, or GBA1. This evidence concerns the gene CHCHD2 and Parkinson disease.